Report copyright - Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer...Cetuximab-resistant (T24 PR1, T24 PR2 and T24 PR3) and -sensitive (T24) bladder cancer cells were plated, and after
Please pass captcha verification before submit form